<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623099</url>
  </required_header>
  <id_info>
    <org_study_id>Strawn PrEcISE</org_study_id>
    <secondary_id>R01HD099775</secondary_id>
    <nct_id>NCT04623099</nct_id>
  </id_info>
  <brief_title>Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)</brief_title>
  <acronym>PrEcISE</acronym>
  <official_title>Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, 12-week study will consist include132 anxious youth who are randomized&#xD;
      (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization&#xD;
      (1:1) will be stratified by sex and metabolizer status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, controlled trial compares pharmacogenetically-guided and standard dosing of&#xD;
      escitalopram in adolescents (12-17 years of age) with anxiety disorders. In this study, the&#xD;
      investigators will examine these two dosing strategies in terms of efficacy (Aim 1) and&#xD;
      tolerability (Aim 2).&#xD;
&#xD;
      The investigators propose to recruit 132 adolescents (age 12-17 years, inclusive) with&#xD;
      generalized, separation and/or social anxiety disorder (pediatric anxiety trial).1 This will&#xD;
      allow investigators to evaluate whether pharmacogenetically-guided escitalopram dosing&#xD;
      improves efficacy and tolerability in outpatient adolescents aged 12-17 years with anxiety&#xD;
      disorders. Eligible patients will be randomized to: (1) standard escitalopram dosing or (2)&#xD;
      pharmacogenetically-guided dosing for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This randomized, controlled trial compares pharmacogenetically-guided and standard dosing of escitalopram in adolescents (12-17 years of age) with anxiety disorders. In this study, investigators will examine these two dosing strategies in terms of efficacy (Aim 1) and tolerability (Aim 2). Investigators will also evaluate the relationship between pharmacodynamic variables and treatment response.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Anxiety Rating Scale severity score</measure>
    <time_frame>Baseline to Week 12/Early Termination</time_frame>
    <description>Change from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score. The PARS is a clinician-rated instrument for assessing the severity of anxiety symptoms associated with common anxiety disorders in children and adolescents. The PARS score is derived by summing 5 of the 7 severity/impairment/interference items (2, 3, 5, 6, and 7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability-Activation</measure>
    <time_frame>Baseline to Week 12/Early Termination</time_frame>
    <description>Emergence of activation based on the Treatment-Emergent Activation and Suicidality Assessment Profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Standard dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacogenetically-guided escitalopram dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.</description>
    <arm_group_label>Pharmacogenetically-guided escitalopram dosing</arm_group_label>
    <arm_group_label>Standard dosing</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written, informed assent and consent.&#xD;
&#xD;
          2. Patients, parent/guardian must be fluent in the English.&#xD;
&#xD;
          3. 12 to 17 years of age, inclusive, at Visit 1.&#xD;
&#xD;
          4. Patients must meet DSM-512 criteria for generalized, social and/or separation anxiety&#xD;
             disorder, confirmed by the MINI-KID.&#xD;
&#xD;
          5. PARS score ≥15 at Visit 1 and Visit 2.&#xD;
&#xD;
          6. No initiation of psychotherapy within 8 weeks of screening (Visit 1). Current therapy&#xD;
             much be stable for ≥2 months prior to baseline (Visit 2).&#xD;
&#xD;
          7. Clinical Global Impressions-Severity (CGI-S) score ≥4 at Visits 1 &amp; 2.&#xD;
&#xD;
          8. Caregiver who is willing to consent to be responsible for safety monitoring of the&#xD;
             patient, provide information about the patient's condition, oversee the administration&#xD;
             of the investigational product.&#xD;
&#xD;
          9. No clinically significant abnormalities on physical examination and EKG.&#xD;
&#xD;
         10. Negative pregnancy test at Visit 1 in females.&#xD;
&#xD;
         11. Negative urine drug screen at Visit 1.&#xD;
&#xD;
         12. Sexually active patients must practice a reliable method of contraception that will&#xD;
             continue for the duration of the study and for a minimum of 30 days following the end&#xD;
             of study participation. Reliable methods of contraception are defined below; other&#xD;
             forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted:&#xD;
&#xD;
               1. Surgical sterilization&#xD;
&#xD;
               2. Oral contraceptives (e.g. estrogen-progestin combination or progestin)&#xD;
&#xD;
               3. Transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections&#xD;
                  (e.g., Depo-Provera)&#xD;
&#xD;
               4. Vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g.,&#xD;
                  Implanon, Norplant II/Jadelle)&#xD;
&#xD;
               5. An intrauterine device&#xD;
&#xD;
               6. Diaphragm plus condom. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Co-occurring DSM-5 mood disorder (except persistent depressive disorder, unspecified&#xD;
             depressive disorder, provided that the primary diagnosis is an anxiety disorder),&#xD;
             eating, bipolar or psychotic disorders.&#xD;
&#xD;
          2. A lifetime diagnosis of an intellectual disability.&#xD;
&#xD;
          3. A significant history of trauma exposure.&#xD;
&#xD;
          4. A history of SSRI treatment within 12 weeks of baseline or current treatment with a&#xD;
             medication with psychiatric effects that requires &gt;5 half-lives for washout History of&#xD;
             non-response to &gt;2 SSRIs.&#xD;
&#xD;
          5. Allergy, intolerance, non-response or hypersensitivity to escitalopram. Major&#xD;
             neurological or medical illness or head trauma with ≥5 minutes loss of consciousness.&#xD;
&#xD;
          6. Alcohol or substance use disorder within the past 6 months (nicotine use is&#xD;
             permitted).&#xD;
&#xD;
          7. Psychotherapy initiated within 8 weeks of screening (Visit 1), or plans to&#xD;
             initiate/change therapy during the study.&#xD;
&#xD;
          8. Pregnant, breastfeeding, lactating, and/or planning to become pregnant during the&#xD;
             study or within 30 days following the end of study participation.&#xD;
&#xD;
          9. Positive urine pregnancy test.&#xD;
&#xD;
         10. A positive urine drug screen.&#xD;
&#xD;
         11. Patient lives &gt;90 minutes from UC or unable to attend follow-up visits. Suicide risk&#xD;
             as determined by either: (1) any suicide attempt within the past 6 months and/or (2)&#xD;
             significant risk at Visit 1 (Screening) or Visit 2 (Baseline), as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         12. QTc &gt;450 in males or &gt;460 in females (prolonged QTc based on American Heart&#xD;
             Association recommendations for Standardization and Interpretation of the EKG&#xD;
&#xD;
         13. Patients who are unable to swallow capsules.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R. Strawn,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura B. Ramsey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacquelyn Birkley, BS</last_name>
    <phone>(513) 558-2931</phone>
    <email>birklejn@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley Specht, BBA</last_name>
    <phone>(513) 558-2868</phone>
    <email>huckabam@ucmail.uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati, Department of Psychiatry &amp; Behavioral Neuroscience</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah A. Mossman, MACPR</last_name>
      <phone>513-558-2866</phone>
      <email>mossmash@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacquelyn Birkley</last_name>
      <phone>513-558-7700</phone>
      <email>birklejn@ucmail.uc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Jeffrey Strawn, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Kids</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

